Home

United Therapeutics Corporation - Common Stock (UTHR)

352.73
-1.45 (-0.41%)

United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapies to treat chronic and life-threatening conditions, primarily in the fields of pulmonary hypertension and organ transplantation

Through its research efforts, the company aims to create and provide advanced medications that improve the quality of life for patients with severe health challenges. United Therapeutics is also engaged in initiatives to promote organ donation and transplantation, working towards enhancing the availability of organs for patients in need.

SummaryNewsPress ReleasesChartHistoricalFAQ
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.investors.com
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via Investor's Business Daily · January 9, 2025
How Is The Market Feeling About United Therapeutics?benzinga.com
Via Benzinga · January 1, 2025
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · December 11, 2024
How Is The Market Feeling About United Therapeutics?benzinga.com
Via Benzinga · November 26, 2024
Earnings Outlook For United Therapeuticsbenzinga.com
Via Benzinga · October 29, 2024
Decoding 7 Analyst Evaluations For United Therapeuticsbenzinga.com
Via Benzinga · October 21, 2024
The Analyst Landscape: 7 Takes On United Therapeuticsbenzinga.com
Via Benzinga · October 21, 2024
$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · October 15, 2024
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgradeinvestors.com
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Via Investor's Business Daily · October 15, 2024
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profitsinvestors.com
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Via Investor's Business Daily · October 14, 2024
Peering Into United Therapeutics's Recent Short Interestbenzinga.com
Via Benzinga · October 10, 2024
A Look Into United Therapeutics Inc's Price Over Earningsbenzinga.com
Via Benzinga · October 3, 2024
U.S. Stock: United Therapeutics Corptalkmarkets.com
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease.
Via Talk Markets · September 25, 2024
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · September 24, 2024
Key Takeaways From United Therapeutics Analyst Ratingsbenzinga.com
Via Benzinga · September 23, 2024
The Analyst Verdict: United Therapeutics In The Eyes Of 8 Expertsbenzinga.com
Via Benzinga · August 20, 2024
FDA Battles Backlog of Drug Factory Inspections Since COVID-19benzinga.com
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via Benzinga · September 6, 2024
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmarkinvestors.com
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
Via Investor's Business Daily · September 5, 2024
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbersinvestors.com
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.
Via Investor's Business Daily · August 29, 2024
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · August 28, 2024
Biohaven Stock Earns Relative Strength Rating Upgradeinvestors.com
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.
Via Investor's Business Daily · August 21, 2024
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Ratinginvestors.com
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.
Via Investor's Business Daily · August 21, 2024
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdingsbenzinga.com
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities and Exchange Commission on Aug. 9.
Via Benzinga · August 19, 2024
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · August 19, 2024
Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38%investors.com
The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI.
Via Investor's Business Daily · August 19, 2024